ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.44
-0.01 (-0.11%)
At close: Feb 19, 2026, 4:00 PM EST
9.62
+0.18 (1.91%)
After-hours: Feb 19, 2026, 7:39 PM EST
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $32.50M in the quarter ending September 30, 2025, with 1,471.62% growth. This brings the company's revenue in the last twelve months to $142.77M, up 5,459.66% year-over-year. In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth.
Revenue (ttm)
$142.77M
Revenue Growth
+5,459.66%
P/S Ratio
6.54
Revenue / Employee
$854,922
Employees
167
Market Cap
933.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | 17.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.76B |
| Valneva SE | 211.09M |
| CytomX Therapeutics | 113.63M |
| UroGen Pharma | 96.52M |
| Theravance Biopharma | 80.33M |
| AbCellera Biologics | 35.33M |
| Aktis Oncology | 5.56M |
SPRY News
- 5 days ago - ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
- 9 days ago - ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 17 days ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire
- 4 weeks ago - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use - GlobeNewsWire
- 5 weeks ago - Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Benzinga
- 7 weeks ago - neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript - Seeking Alpha